Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berlin

Showing results (211-220 of 248) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumorsA Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Arzneimittel-Forschung|February 23, 2000
Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in miceC L Chen, S A Chandra, S Kim, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|August 10, 2000
The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 miceC L Chen, A M Chandra, S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Investigational New Drugs|April 3, 2014
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancerJohanna C Bendell, Heinz-Josef Lenz, Theresa Ryan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research PhysiciansDavid E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Pageof 25

Showing results (211-220 of 248) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumorsA Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Arzneimittel-Forschung|February 23, 2000
Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in miceC L Chen, S A Chandra, S Kim, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|August 10, 2000
The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 miceC L Chen, A M Chandra, S Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.
Investigational New Drugs|April 3, 2014
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancerJohanna C Bendell, Heinz-Josef Lenz, Theresa Ryan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research PhysiciansDavid E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Pageof 25